Skip to main content

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-146/Study 111 trial

Chung-Han Lee reports the final analysis of KEYNOTE-146/Study 111 trial of lenvatinib plus pembrolizumab in metastatic clear-cell renal cell carcinoma after immune checkpoint inhibitor therapy (4:57).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read transcript

2021 Genitourinary Cancers Symposium

View our abstract recommendations for the upcoming virtual meeting

Image Credits